What people are actually doing — and whether the reasoning holds

What is circulating

Deliberately staying under the label's therapeutic range indefinitely, framed as a metabolic maintenance or longevity practice rather than as weight treatment.

The stated rationale

That lower exposure retains appetite regulation and metabolic benefit while avoiding gastrointestinal side effects and cost.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Cagrilintide or other amylin analogues—Claimed additive appetite suppression through a separate receptor.
• Resistance training and a protein target—The one pairing with real evidence behind it — protects lean mass during loss.

Where we observed it

Longevity podcasts and newsletters, telehealth marketing, and metabolic-health forums reviewed by our editorial team.

What to be aware of

• DocumentedCompounded and grey-market GLP-1 products have been linked to dosing errors and adverse events, with regulators in several jurisdictions issuing warnings. Concentration error is a bigger practical risk here than the molecule.
• Expected from pharmacologyDelayed gastric emptying alters absorption of oral medicines at any exposure — most consequential for drugs with a narrow therapeutic window.
• Expected from pharmacologyLean mass is lost alongside fat mass. Over an indefinite practice, without training and protein, that accumulates in a way a short course does not.

What is circulating

Using an incretin therapy purely for appetite suppression, with no training programme and no attention to protein, often while eating substantially less overall.

The stated rationale

That the drug is doing the work, so training and diet composition matter less.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Nothing — this practice is defined by the absence of support—The drug is treated as sufficient on its own.

Where we observed it

Consistently reported by clinicians and coaches in our own network, and visible across weight-loss forums.

What to be aware of

• DocumentedLoss of lean mass alongside fat mass is consistently observed in incretin trials, and is worse at faster rates of loss.
• Expected from pharmacologyAppetite suppression cuts across all foods rather than selectively, so reduced intake without attention to composition tends to produce inadequate protein and micronutrients.
• Expected from pharmacologyFunctional decline matters most in older adults, where lean mass loss carries fall and fracture consequences a younger person would not notice.

What is circulating

A releasing-hormone analogue combined with a secretagogue, dosed away from food and usually timed at night to sit with the natural overnight growth-hormone pulse.

The stated rationale

The two act on different receptors — one on the GHRH receptor, one on the ghrelin receptor — so combining them is expected to produce a larger pulse than either alone, while preserving pulsatility in a way exogenous growth hormone does not.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• MK-677 (ibutamoren)—An oral secretagogue added for continuous elevation rather than pulsatile release.
• A caloric surplus and progressive training—The community generally recognises the peptides do nothing without this.
• GLP-1 agonists, in 'recomp' protocols—Attempting simultaneous fat loss and lean gain. Mechanistically these pull in opposite directions on energy availability.

Where we observed it

Bodybuilding and anti-ageing forums, coaching group materials, and clinic marketing reviewed by our editorial team.

What to be aware of

• DocumentedSecretagogues raise IGF-1 and, for MK-677 specifically, produce documented water retention and a signal toward reduced insulin sensitivity.
• Expected from pharmacologyGhrelin-receptor agonists increase appetite. In a fat-loss context this works directly against the goal, which is why the GLP-1 pairing is internally contradictory.
• TheoreticalWhether sustained IGF-1 elevation carries long-term risk in healthy adults is an open question. Observational associations exist in both directions and are not a basis for either alarm or reassurance.

What is circulating

Running an incretin therapy for fat loss while simultaneously running secretagogues, on the reasoning that one handles fat and the other protects or builds muscle.

The stated rationale

That the growth-hormone axis will offset the lean-mass loss that incretin-driven weight loss is known to cause.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• High protein intake and resistance training—Where present, this is doing most of the work being credited to the stack.

Where we observed it

Body-recomposition forums, coaching programmes, and telehealth 'stack' marketing reviewed by our editorial team.

What to be aware of

• DocumentedBoth components independently affect glucose handling in opposite directions. Layering them makes any glycaemic problem harder to attribute and harder to manage.
• Expected from pharmacologyRunning several compounds concurrently means an adverse reaction cannot be traced to a cause, so the usual response is to stop everything and lose the information.
• Expected from pharmacologyGrey supply of two compounds roughly doubles exposure to a mislabelled or contaminated batch.

What is circulating

A copper-peptide serum applied immediately after home or clinic microneedling, on the reasoning that the channels improve penetration.

The stated rationale

That the peptide is too large to cross intact skin well, so creating temporary channels dramatically increases how much reaches the dermis.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Retinoids—Widely combined, though the community itself debates whether they should be applied in the same session.
• Vitamin C serums—Frequently discouraged in the same application even within the community, on stability grounds.

Where we observed it

Skincare communities, aesthetic clinic protocols, and product marketing reviewed by our editorial team.

What to be aware of

• Expected from pharmacologyApplying a non-sterile cosmetic formulation to breached skin is a recognised infection and granuloma route. Preservatives that are safe on intact skin are not necessarily safe in the dermis.
• Expected from pharmacologyPost-inflammatory hyperpigmentation risk from needling is higher in deeper skin tones, and is a function of the procedure rather than the peptide.
• TheoreticalWhether repeated enhanced copper delivery has any local accumulation effect has not been studied. An open question, not a documented harm.

What is circulating

Occasional, situation-linked use of a melanocortin agonist. The community frequently discusses the approved compound and an unapproved analogue interchangeably, as though the difference were only price.

The stated rationale

That melanocortin pathway activation affects central sexual arousal rather than vascular function, so it works differently from PDE5 inhibitors and for a different set of people.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• PDE5 inhibitors—Combined for what is described as complementary central and vascular action. Both can lower blood pressure.
• Anti-nausea medication—Taken pre-emptively, which is itself a signal about how commonly the primary effect occurs.

Where we observed it

Sexual-health forums, men's health communities, and grey vendor marketing reviewed by our editorial team.

What to be aware of

• DocumentedNausea is common and dose-related — common enough that pre-emptive anti-emetics are a normal part of community practice.
• DocumentedMelanotan II specifically has documented associations with new and changing melanocytic naevi, and case reports of melanoma following use. Dermatological review before and during use is a reasonable precaution, and this is a genuine evidence-backed concern rather than a speculative one.
• DocumentedPriapism has been reported with melanotan II. It is a urological emergency, not an inconvenience, and delayed presentation risks permanent damage.
• Expected from pharmacologyTransient blood-pressure changes are expected from the mechanism, which matters when combined with PDE5 inhibitors or antihypertensives.

What is circulating

Adding a gonadotropin or GnRH analogue alongside exogenous testosterone, intended to maintain testicular function and fertility that suppression would otherwise cost.

The stated rationale

That exogenous testosterone suppresses the HPG axis, so supplying downstream signal maintains testicular volume and spermatogenesis during therapy.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Testosterone therapy—This practice exists only in that context — it is a countermeasure, not standalone.
• Aromatase inhibitors—Added for oestradiol management. Frequently self-managed without bloodwork, which is where it goes wrong.

Where we observed it

Men's health forums, TRT clinic protocols, and endocrinology discussion reviewed by our editorial team.

What to be aware of

• Expected from pharmacologyAromatase inhibitors added without oestradiol monitoring can drive levels too low, with consequences for bone density, lipids, mood and libido. Over-suppression is a common and avoidable self-management error.
• Expected from pharmacologyUnderlying testosterone therapy requires haematocrit and prostate monitoring regardless of what is added alongside it.
• DocumentedThese are prescription medicines. Grey-sourced material carries the identity and concentration risks documented across this category.

What is circulating

The two run together for tendon, ligament or muscle injuries that have not resolved with rehabilitation, usually alongside continued training rather than instead of it.

The stated rationale

That the two act on different repair pathways — angiogenesis and growth-factor signalling versus actin regulation and cell migration — so combining them covers more of the healing process.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Progressive loading rehabilitation—Where present, this is the component with actual human outcome evidence behind it.
• Oral BPC-157 for gut symptoms—Run concurrently on the reasoning that the original research was gastrointestinal.

Where we observed it

Long-running injury-recovery forum threads, podcast interviews with coaches, and paid coaching group materials reviewed by our editorial team.

What to be aware of

• Expected from pharmacologyAnything promoting tissue growth signalling acts systemically, not only at the injured site. What that means over months in humans has not been characterised.
• DocumentedIndependent testing has repeatedly found mislabelled and impure peptide products. Two compounds roughly doubles exposure to a bad batch and makes attribution impossible.
• TheoreticalWhether sustained growth-factor signalling carries oncological risk in humans is unstudied. We flag it as unstudied, not as a known harm — the evidence does not point either way.

What is circulating

Short courses framed as mitochondrial support, usually tied to training blocks or to subjective fatigue, and often tracked with wearable recovery metrics.

The stated rationale

That mitochondrial-derived peptides act as metabolic stress signals, so supplying them exogenously should improve mitochondrial function and therefore energy and exercise capacity.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• NAD+ precursors—Combined as general mitochondrial support on overlapping reasoning.
• Structured endurance training—The intervention with by far the strongest evidence for mitochondrial adaptation — and often the confound.

Where we observed it

Longevity forums, biohacking communities, and clinic marketing reviewed by our editorial team.

What to be aware of

• Expected from pharmacologyNo human safety dataset of adequate size or duration exists for MOTS-c. Absence of reported harm reflects absence of study.
• DocumentedInjection-site reactions are the most commonly reported adverse effect for elamipretide in trial settings.
• Expected from pharmacologyWearable recovery scores respond to sleep, alcohol, illness and training load. Attributing a change to a compound while those vary is not a measurement.

What is circulating

Brief courses repeated once or twice a year as a biological-ageing maintenance practice, often tracked with a consumer epigenetic age test.

The stated rationale

Rests almost entirely on a claimed effect on telomerase activity, plus older cohort reports suggesting mortality differences.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Consumer epigenetic age testing—Used as the outcome measure, which is the weakest part of the practice.

Where we observed it

Longevity forums, anti-ageing clinic marketing, and podcast discussion reviewed by our editorial team.

What to be aware of

• TheoreticalIf a compound genuinely increased telomerase activity, the oncological implications would need study. That study has not been done — a reason the practice is unstudied, not evidence it causes harm.
• Expected from pharmacologyNo human safety dataset of adequate size or duration. Absence of reported harm reflects absence of systematic study.

What is circulating

Lyophilised material from research-supply vendors, reconstituted at home with bacteriostatic water, stored in a domestic fridge and drawn from over an extended period.

The stated rationale

Cost and access — the same molecule at a fraction of pharmacy pricing, with the research-use label treated as a formality.

Reported in the community’s own terms. Not our position.

Commonly stacked with

• Bacteriostatic water sold alongside injectables—Convenience. Regulators have treated exactly this pairing as evidence of intended human use.

Where we observed it

Ubiquitous across peptide forums and vendor-adjacent chat groups, including step-by-step community documents.

What to be aware of

• DocumentedIndependent testing has repeatedly found peptide products that are mislabelled, underfilled or contaminated. This is the best-evidenced risk in the entire category.
• DocumentedRegulators have linked compounded and grey-market products to dosing errors and adverse events including hospitalisations.
• Expected from pharmacologySterility and endotoxin are separate properties and neither survives casual handling. A clean-looking solution tells you nothing about endotoxin load.
• Expected from pharmacologyPeptides degrade in solution through oxidation, deamidation and aggregation. Material late in a vial is not the material that was tested.